Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New drug brensocatib now available for bronchiectasis patients who completed landmark trial
Disease control APPROVED_FOR_MARKETINGThis program provides early access to brensocatib for people with non-cystic fibrosis bronchiectasis who finished the ASPEN study. Participants must have already taken brensocatib without serious side effects. The goal is to continue managing the disease, not to cure it.
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New hope for PAH patients: Long-Term inhaled therapy under study
Disease control OngoingThis study looks at the long-term safety and tolerability of an inhaled powder called treprostinil palmitil (TPIP) for people with pulmonary arterial hypertension (PAH). About 91 adults who completed earlier TPIP studies will continue treatment and be monitored for side effects a…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New hope for painful skin condition: brensocatib enters phase 2b trial
Disease control OngoingThis study tests whether brensocatib can reduce painful lumps and abscesses in people with moderate to severe hidradenitis suppurativa (HS). About 214 adults will receive either brensocatib or a placebo for 16 weeks. The goal is to see if the drug improves skin lesions and overal…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC